Result (English)

Paper

> Read more

Conference

  • Kumamaru H, Takeuchi Y, Kohsaka S, Matsui H, Yasunaga H, Miyata H. Comparative effectiveness of First-line SGLT2 inhibitor use on heart failure hospitalization among patients with type 2 diabetes mellitus; A target trial emulation (Poster presentation). 38th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. 2022 Aug, Copenhagen/Online.
  • Takeuchi Y, Iwagami M, Ono S, Yasunaga H. Serious adverse effects after COVID-19 vaccination in Japan: Analysis using administrative claims data linked with vaccination registry. 14th Asian Conference on Pharmacoepidemiology. 2022 Oct, Tainan/Online.
  • Sawamoto R, Matsuyama Y. Standardized mortality ratio-weighted power prior approach for covariate-adjusted borrowing of historical control data. 2021 Joint Statistical Meetings, Online. Aug 2021.
  • Takeuchi Y, Hagiwara Y, Matsuyama Y. Marginal structural Cox models in nested case-control studies with time-varying treatments. 42nd Conference of the International Society for Clinical Biostatistics. Online. Jul 2021.
  • Sakamoto A, Aizawa K, Uemura K, Komuro I, Matsuyama Y, Nagai R. Increased serum immunoglobulin G4 level is a novel predictor of cardiovascular events independent of established risk factors: Results from the REAL-CAD study. American Heart Association Scientific Sessions 2020 November 14-16, Dallas, Texas
  • Sakamoto A, Aizawa K, Uemura K, Komuro I, Matsuyama Y, Nagai R. Increased serum immunoglobulin G4 level is a novel predictor of cardiovascular events independent of established risk factors: Results from the REAL-CAD study. American Heart Association Scientific Sessions 2020 November 14-16, Dallas, Texas
  • Takeuchi Y. Kumamaru H, Hagiwara Y, Matsui H, Yasunaga H, Miyata H, Matsuyama Y, Risk of Sodium-Glucose Cotransporter-2 Inhibitor on the Incidence of Urinary Tract Infection among Diabetic Patients in Japan: A Nationwide Cohort Study (poster presentation). ICPE All Access. Online. Sep 2020.
  • Hagiwara Y, Kawahara T, Shiroiwa T. What is a valid mapping algorithm in cost-utility analyses? An answer from a missing data perspective. International Society for Pharmacoeconomics and Outcome Research Europe 2019. Copenhergen, Denmark. November 2019. PNS323.
  • Kashiwabara K, Matsuyama Y. Treatment effect estimation in an efficient adaptive design: comparison with the exact estimation method. 40th Annual Conference of the ISCB 2019, 14-18 July, Leuven, Belgium.
  • Satoi S, Unno M, Motoi F, Matsuyama Y, Matsumoto I, Aosasa S, Shirakawa H, Wada K, Fujii T, Yoshitomi H, Takahashi S, Sho M, Ueno H, Yamamoto H, Kosuge T. The effect of neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic cancer (Randomized phase II/III trial; Prep-02/JSAP-05). ASCO 2019, May 31-June 4, Chicago, USA

> Read more

Symposium

> Read more

Publication

  • Oba K, Kuchiba A. Sample Size Calculations for Phase III Trials in Oncology. In: Halabi S, Michiels S (Eds.) Textbook of Clinical Trials in Oncology: A Statistical Perspective. CRC Press, FL, 2019
  • Shinozaki T, Matsuyama Y. Data analysis on real world data: an overview. In: Sudoh, O. (editor). Epidemiologic Research on Real World Medical Data in Japan. Switzerland: Springer International Publishing, 2019 (forthcoming).
  • Oba K, Paoletti X. Evaluation of Surrogate Endpoints using a Meta-Analysis Approach with Individual Patient Data: Summary of a Gastric Cancer Meta-Analysis Project. In: Matsui S, Crowley J(Eds.) Frontiers of Biostatistical Methods and Applications in Clinical Oncology. Springer Singapore, Singapore, 2017
  • Buyse M, Molenberghs G, Paoletti X, Oba K, Alonso A,Van der Elst W, Burzykowski T. Statistical evaluation of surrogate endpoints in cancer clinical trials. In: Oncology Clinical Trials: Successful Design, Conduct and Analysis. Second Edition, Demos Medical Publishing, NY, 2017

> Read more

TOP